GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact Teva banks on blockbuster Austedo sales as COVID-19, Copaxone generics take their toll Lynch: Enrollment in Aetna's ACA exchange plans lower than expected Bausch Health files for Solta IPO as its three-way split nears completion Senators to craft major mental health package with focus on reforming pay parity, expand telehealth Checkmate plucks BMS exec Bash to be new CEO Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms Element Biosciences acquires Loop Genomics to add long-read tech to DNA sequencing platform Silence drug reduces cardiovascular disease risk factor as plans to 'scale up' drug development get underway Orthox spins up $12M for trials of spider-inspired artificial cartilage implant Karyopharm ready to take new Xpovio indication to the FDA but analysts hold out for details Thirty Madison to merge with Nurx, expanding virtual specialty care services Featured Story | By Nick Paul Taylor Shortly after becoming GlaxoSmithKline’s chief scientific officer, Hal Barron highlighted GSK3326595 as one of four early-stage cancer programs to watch. Today, with Barron’s time at the company nearing its end, GSK axed the PRMT5 inhibitor and sibling molecule GSK3368715 from its pipeline. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Teva Pharmaceutical has a lot riding on tardive dyskinesia (TD) drug Austedo and migraine med Ajovy. Hamstrung by the pandemic, Austedo came just shy of meeting Teva’s 2021 sales projection. Still, 2022 could be the year the drug breaks the blockbuster barrier, executives said Wednesday. read more By Paige Minemyer CVS Health posted $1.3 billion in profit for the fourth quarter of 2021, up from $973 million in the prior-year quarter. read more By Conor Hale In addition to Solta, the company’s major eye health subsidiary Bausch + Lomb will hold its own IPO, as announced in January. Bausch Health will take over the remaining drug portfolio and continue as Bausch Pharma. read more By Robert King Bipartisan senators are undertaking a major effort to craft new legislation to improve mental health care access, including reforms to pay parity and access to telehealth. read more By Max Bayer Checkmate Pharmaceuticals has hired Bristol Myers Squibb SVP Alan Bash as president and CEO, completing a more than three-month search for someone to fill the top post. The company hopes Bash will be able to replicate his success overseeing the U.S. launch of Opdivo. read more By Ben Adams The FDA only recently approved Vabysmo, at the end of January, but Roche is already hyping up its launch, as it hopes to go toe-to-toe against ophthalmology powerhouse Eylea from Regeneron and Bayer. read more By Andrea Park With the close of the deal, Tuval Ben-Yehezkel, Ph.D., the CEO and founder of Loop, has been named senior director of applications on Element’s leadership team. read more By Kyle LaHucik Silence Therapeutics is mum no more on its short interfering RNA therapy, which has been found to significantly reduce levels of an independent risk factor for cardiovascular disease. read more By Andrea Park Spider-inspired technology isn’t just for comic book characters anymore. A biomaterial that’s made of silk and takes its construction cues from the strength of spiderwebs has the potential to replace worn-down cartilage around the human knee and encourage the natural tissue to regrow around it, according to its makers. read more By Eric Sagonowsky After a tough path to the market, Karyopharm scored a series of FDA approvals for Xpovio in recent years for multiple myeloma and diffuse large B-cell lymphoma. Now, it's looking to take the momentum forward into another cancer indication and move the drug to an earlier line of treatment, which would open up a bigger market. read more By Rebecca Torrence Telehealth unicorn Thirty Madison and female-focused virtual care provider Nurx are merging, combining online prescriptions for conditions like hair loss and migraines with sexual and reproductive healthcare offerings in a single digital health platform. read more |
| Whitepaper: Reimagining Oncology Clinical Trials with Digital Biomarkers Health metrics enabled by wearables are a big untapped opportunity in oncology clinical trials. Yet, sponsors of cancer clinical trials have been slower to embrace digital outcome measures than their peers in other therapeutic areas. In this paper, we look at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them. Download Now. |
|
